Filtered By:
Condition: Stroke
Drug: Actos

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM), are at least 50 years old, have cardiovascular disease, and have an hemoglobin A1c value between 6.5% and 8.0%. Eligible participan...
Source: American Heart Journal - October 25, 2013 Category: Cardiology Authors: Jennifer B. Green, M. Angelyn Bethel, Sanjoy K. Paul, Arne Ring, Keith D. Kaufman, Deborah R. Shapiro, Robert M. Califf, Rury R. Holman Tags: Trial Design Source Type: research

{Delta}9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR{gamma} DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE
Conclusions Even though 9–THC and pioglitazone are both protective against MPP+ only 9–THC induces PPAR dependent mitochondrial biogenesis, a mechanism that may be beneficial for the treatment of PD.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Zeissler, M.-L., Eastwood, J., Oliver Hanemann, C., Zajicek, J., Carroll, C. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Parkinson's disease, Stroke Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23-24 October 2013 Source Type: research

Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research

Observational follow‐up of the PROactive Study: a 6‐year update
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - July 22, 2013 Category: Endocrinology Authors: Erland Erdmann, Eric Song, Robert Spanheimer, Anne‐Ruth van Troostenburg de Bruyn, Alfonso Perez Tags: Original Paper Source Type: research

KLF11 mediates PPAR{gamma} cerebrovascular protection in ischaemic stroke
Peroxisome proliferator-activated receptor gamma (PPAR) is emerging as a major regulator in neurological diseases. However, the role of (PPAR) and its co-regulators in cerebrovascular endothelial dysfunction after stroke is unclear. Here, we have demonstrated that (PPAR) activation by pioglitazone significantly inhibited both oxygen–glucose deprivation-induced cerebral vascular endothelial cell death and middle cerebral artery occlusion-triggered cerebrovascular damage. Consistent with this finding, selective (PPAR) genetic deletion in vascular endothelial cells resulted in increased cerebrovascular permeability and ...
Source: Brain - April 1, 2013 Category: Neurology Authors: Yin, K.-J., Fan, Y., Hamblin, M., Zhang, J., Zhu, T., Li, S., Hawse, J. R., Subramaniam, M., Song, C.-Z., Urrutia, R., Lin, J. D., Chen, Y. E. Tags: Original Articles Source Type: research

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news